



Company Announcement

Tuesday 31 August 2010
Melbourne, Australia

Resignation of Non-Executive Director

Clinuvel Pharmaceuticals Limited (**ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY**) today announced the resignation of Non-Executive Director Dr Roger Aston, effective September 1.

Dr Aston was appointed to Clinuvel's Board in March 2005 and was Executive Chair of the Board from September 2005 until December 2007. During his time with Clinuvel, Dr Aston has overseen a total refocus of the program for SCENESSE® (afamelanotide) as a first-in-class drug, and has since taken an active Non-Executive role, including chairing the company's Audit & Risk Committee.

Dr Aston said:

“As Clinuvel progresses its program for SCENESSE® towards commercialisation, I must focus my energies on my role as Executive Chairman and Chief Executive Officer of Halcyon Pharmaceuticals. I am proud of where Clinuvel stands today and excited by its prospect to realise its potential.”

Clinuvel's Chairman, Mr Stan McLiesh, said:

“Dr Aston has made a very valuable contribution to the direction of the company over the past five years and, on behalf of the Board, I thank him for his insight, energy and effort to advance our program of SCENESSE®. I wish Dr Aston well in his future endeavours.”

As announced on June 28, Non-Executive Director Mrs Brenda Shanahan will assume the role chairing Clinuvel's Audit and Risk Committee.

- End -

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Ltd is a leading and innovative Australian company focused on the development of SCENESSE® (afamelanotide), its proprietary first-in-class photoprotective drug. Clinuvel has identified a number of groups of patients with a clinical need for photoprotection and one with a need for repigmentation therapy. Currently, Clinuvel is in its final stages to complete testing of SCENESSE® in Phase II and III trials in Australia, Europe and the United States. Clinuvel's ongoing focus is to demonstrate the safety and efficacy of SCENESSE®. Pending positive clinical results, Clinuvel aims to file SCENESSE® for its first market approval for the orphan indication porphyria (EPP).

Clinuvel's initial focus is to test SCENESSE® in four clinical indications currently being trialled:

Indication	Description	Clinical Trial Status
Erythropoietic Protoporphyrria (EPP)	Absolute sun/UV intolerance	Phase III trial full results reported July 2010 Confirmatory Phase III trial approved August 2009
Actinic Keratosis (AK) and Squamous Cell Carcinoma (SCC) in Organ Transplant Recipients (OTRs)	Skin cancer in transplant patients	Phase II trial started October 2007
Polymorphic Light Eruption (PLE / PMLE)	Severe sun/UV poisoning	Phase III trial preliminary results reported December 2009
Nonsegmental Vitiligo (NSV)	Pigmentary disorder	Phase II pilot trial to commence in 2010

Phase I and II human clinical trials using SCENESSE® have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date. Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of SCENESSE®.

For more information go to <http://www.clinuvel.com>.

For more information contact:

Europe: Daniela Schaefer, Head of Business Operations Europe, Clinuvel AG T: +41 41 767 45 45
Australia: Clinuvel Pharmaceuticals Ltd Melbourne T: +61 3 9660 4900
E: investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, SCENESSE® (afamelanotide) for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

**Level 11 / 330 Collins Street
Melbourne, Victoria 3000
Australia**

**T +61 3 9660 4900
F +61 3 9660 4999**

www.clinuvel.com